Loomis Sayles & Co. L P Acquires 78,708 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Loomis Sayles & Co. L P raised its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 15.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 578,024 shares of the company’s stock after purchasing an additional 78,708 shares during the quarter. Loomis Sayles & Co. L P owned 1.20% of Mirum Pharmaceuticals worth $23,901,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the company. Jones Financial Companies Lllp grew its holdings in Mirum Pharmaceuticals by 100.0% during the 4th quarter. Jones Financial Companies Lllp now owns 714 shares of the company’s stock valued at $30,000 after purchasing an additional 357 shares during the last quarter. Legato Capital Management LLC raised its holdings in shares of Mirum Pharmaceuticals by 7.9% in the 4th quarter. Legato Capital Management LLC now owns 13,395 shares of the company’s stock valued at $554,000 after purchasing an additional 977 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in Mirum Pharmaceuticals by 10.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,179 shares of the company’s stock worth $421,000 after buying an additional 1,003 shares in the last quarter. Rhumbline Advisers boosted its position in Mirum Pharmaceuticals by 2.4% during the 4th quarter. Rhumbline Advisers now owns 53,113 shares of the company’s stock valued at $2,196,000 after acquiring an additional 1,236 shares in the last quarter. Finally, Swiss National Bank increased its holdings in shares of Mirum Pharmaceuticals by 1.9% in the 4th quarter. Swiss National Bank now owns 70,300 shares of the company’s stock valued at $2,907,000 after acquiring an additional 1,300 shares during the period.

Mirum Pharmaceuticals Price Performance

Shares of MIRM stock opened at $45.99 on Friday. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $23.14 and a fifty-two week high of $54.23. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34. The firm has a market capitalization of $2.25 billion, a price-to-earnings ratio of -22.77 and a beta of 1.04. The stock’s 50-day simple moving average is $48.01 and its 200-day simple moving average is $43.86.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its earnings results on Wednesday, February 26th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.22). Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The company had revenue of $99.41 million for the quarter, compared to analysts’ expectations of $96.64 million. As a group, equities analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Insider Activity

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 750 shares of the business’s stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total transaction of $32,115.00. Following the sale, the senior vice president now owns 2,926 shares in the company, valued at approximately $125,291.32. The trade was a 20.40 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Christopher Peetz sold 27,279 shares of the stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $44.21, for a total value of $1,206,004.59. Following the completion of the transaction, the chief executive officer now directly owns 138,641 shares in the company, valued at $6,129,318.61. This represents a 16.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 133,679 shares of company stock valued at $6,007,081 over the last ninety days. 22.87% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

MIRM has been the topic of a number of recent research reports. HC Wainwright raised their price objective on Mirum Pharmaceuticals from $66.00 to $72.00 and gave the company a “buy” rating in a research report on Friday, February 28th. Robert W. Baird increased their price target on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an “outperform” rating in a research report on Thursday, February 27th. Ten research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $58.20.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.